Achari R, Laddu A
Pharmaceutical Research and Development Division, Abbott Laboratories, Abbott Park, Illinois 60064.
J Clin Pharmacol. 1992 Jun;32(6):520-3. doi: 10.1177/009127009203200605.
Terazosin (Hytrin; Abbott Laboratories, North Chicago, IL) is a new, selective alpha 1-adrenoceptor blocking agent used on once-a-day basis for therapy of mild-to-moderate hypertension. Its pharmacologic properties are similar to those of prazosin. Terazosin however, differs from prazosin in that its water solubility is 25 times greater than that of prazosin and its elimination half-life is about three times that of prazosin. Greater water solubility facilitates intravenous formulation, and longer half-life allows once-daily administration of terazosin. Terazosin is effective in lowering blood pressure and has a beneficial effect on plasma lipid profile. The major advantage of terazosin compared with prazosin, however, is its long duration of action. Terazosin is safe and effective when used in combination with diuretics and other antihypertensive agents, and in the long-term treatment of patients with mild to moderate essential hypertension.
特拉唑嗪（高特灵；雅培实验室，伊利诺伊州北芝加哥）是一种新型的选择性α1肾上腺素能受体阻滞剂，每日服用一次，用于治疗轻至中度高血压。其药理特性与哌唑嗪相似。然而，特拉唑嗪与哌唑嗪不同，其水溶性比哌唑嗪大25倍，消除半衰期约为哌唑嗪的三倍。更大的水溶性便于静脉制剂的制备，更长的半衰期使特拉唑嗪能够每日给药一次。特拉唑嗪在降低血压方面有效，并且对血浆脂质谱有有益作用。然而，与哌唑嗪相比，特拉唑嗪的主要优点是其作用持续时间长。特拉唑嗪与利尿剂和其他抗高血压药物联合使用时安全有效，可用于轻至中度原发性高血压患者的长期治疗。
